Clinical trials: IBD
Crohn's Disease
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
The primary objective of this study is to evaluate long-term effectiveness of adalimumab in pediatric participants starting a treatment for Crohn's disease in real life conditions, namely to describe the time to loss of clinical…
- Trial name
- LEA (NCT03017014)
- Where
- 24 sites in France
- Volunteers
- 62 people
- Sponsor
- AbbVie
Crohn's Disease
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that…
- Trial name
- NCT01150890
- Testing
- Brodalumab
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Amgen
Severe Ulcerative Colitis
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
The purpose of this study is to evaluate the safety and tolerability of visilizumab in patients with severe ulcerative colitis that has failed to respond to steroid therapy.
- Trial name
- NCT00267306
- Testing
- Visilizumab
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- Facet Biotech
Crohn's Disease
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults with Moderately Severe Crohn's Disease
- Trial name
- NCT00446433
- Testing
- CC-5013
- Where
- 20 sites in United States, France and 2 more
- Volunteers
- 90 people
- Sponsor
- Celgene Corporation
Ulcerative Colitis
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Ulcerative Colitis
- Trial name
- NCT04205643
- Testing
- CT-P13 SC (Infliximab)
- Where
- Poland
- Volunteers
- 548 people
- Sponsor
- Celltrion
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease
- Trial name
- Adherence (NCT01768858)
- Testing
- Adalimumab
- Volunteers
- 96 people
- Sponsor
- AbbVie
Crohn Disease
A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease
This is a study in adults with Crohn's Disease who also have fistulas near the anus. The study has 2 parts. The first part is to find out more about what causes the fistulas.
- Trial name
- NCT03752970
- Testing
- Spesolimab
- Where
- 10 sites in Austria, Belgium and 6 more
- Volunteers
- 27 people
- Sponsor
- Boehringer Ingelheim
Irritable Bowel Syndrome (IBS)
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
- Trial name
- RESTORE (NCT01887002)
- Testing
- ONO-2952
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Ono Pharma USA Inc
Pouchitis
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
This is an open-label pilot study in which all patients will receive AST-120 for 4 weeks. Patients will discontinue antibiotics at study entry.
- Trial name
- NCT00583531
- Testing
- AST-120
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ocera Therapeutics
Crohn's Disease
Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine
This study aims to compare azathioprine versus mesalazine tablets for the prevention of clinical relapse in postoperative Crohn's disease (CD) patients with moderate or severe endoscopic recurrence.
- Trial name
- NCT00946946
- Testing
- Azathioprine, Mesalazine
- Where
- 2 sites in Austria, Germany
- Volunteers
- 78 people
- Sponsor
- Dr. Falk Pharma GmbH
Myalgic Encephalomyelitis, Chronic Fatigue Syndrome
Effect of Probiotics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a neurological disease. Currently there is no effective treatment for ME/CFS due to unclear etiology of the disease.
- Trial name
- NCT04741841
- Testing
- GutMagnific™ H., GutMagnific™ L.
- Where
- Sweden
- Volunteers
- 74 people
- Sponsor
- ImmuneBiotech Medical Sweden AB
Ulcerative Colitis
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
The purpose of this study is to prove the superiority of a 48-weeks treatment with 3.2 g/day delayed-release phosphatidylcholine (LT-02) versus placebo for the maintenance of remission in patients with ulcerative colitis (UC)
- Trial name
- PROTECT-2 (NCT02280629)
- Testing
- LT-02, Mesalamine
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Dr. Falk Pharma GmbH
Irritable Bowel Syndrome
Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome
The purpose of this study was to compare the Efficacy and Safety of Tiropramide HCl and Octylonium bromide in the Treatment of Irritable Bowel Syndrome.
- Trial name
- NCT01629212
- Testing
- Tiropramide HCl 100mg, Octylonium bromide 20mg
- Where
- South Korea
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Ulcerative Colitis
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT06257875
- Testing
- Lutikizumab, Adalimumab
- Where
- 191 sites in United States, Australia and 28 more
- Volunteers
- 156 people
- Sponsor
- AbbVie
Ulcerative Colitis
ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.
This is a multi-center trial in the US and Europe to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis…
- Trial name
- NCT00063830
- Testing
- Alicaforsen
- Where
- United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Atopic Dermatitis, Asthma
A Clinical Study to Evaluate SM17 in Healthy Participants
This is a phase I study in Chinese healthy adult volunteer participants. It aims to evaluate the safety, tolerability, PK profile and immunogenicity of a single dose of SM17 SC in healthy Chinese adult participants.
- Conditions
- Atopic Dermatitis, Asthma, Inflammatory Bowel Disease
- Trial name
- NCT07466940
- Testing
- SM17
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SinoMab BioScience Ltd
Crohn's Disease
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
This is a study to evaluate vedolizumab for injection (300 mg) as a safe and active treatment for Crohn's Disease in adults in China.
- Trial name
- NCT05837897
- Testing
- Vedolizumab IV
- Where
- 41 sites in China
- Volunteers
- 408 people
- Sponsor
- Takeda
Ulcerative Colitis, Crohn's Disease
Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease
Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract.
- Trial name
- NCT06459297
- Where
- 14 sites in South Korea
- Volunteers
- 105 people
- Sponsor
- AbbVie
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's…
- Trial name
- NCT04846959
- Testing
- Risankizumab, Comparator
- Where
- 2 sites in United States
- Volunteers
- 818 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.